What records are connected here?
- Evidence lanes
- 3
- Source years
- 15
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsHormones
Pasireotide is a synthetic cyclic peptide of six amino acids that mimics somatostatin, and the active ingredient in Signifor.1,2 FDA approved Signifor in 2012 for adults with Cushing’s disease for whom pituitary surgery is not an option or has not worked.1,2 In a randomized trial of 162 patients comparing two treatment arms, 15% and 26% had normal urine cortisol at six months. The label warns that it commonly raises blood sugar.1
| What it is | A cyclohexapeptide somatostatin analogue that binds several somatostatin receptor subtypes, including subtype 5, which corticotroph tumors in Cushing’s disease often over-express, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Signifor with an original approval date of December 14, 2012. The cited label has no boxed warning.1,2 |
| Human evidence | One Phase 3, multicenter, randomized trial in 162 patients with Cushing’s disease comparing two treatment arms over six months, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Pasireotide is a cyclohexapeptide, a ring of six amino acids, that acts like the hormone somatostatin, according to the label.1
In the United States it is the active ingredient of Signifor, from Recordati Rare Diseases, according to Drugs@FDA.2
The label states that pasireotide binds somatostatin receptors, and that the pituitary tumor cells that cause Cushing’s disease often over-express receptor subtype 5.1
The label states that treatment suppresses secretion of ACTH, the pituitary hormone that drives cortisol, which may lower cortisol levels, sometimes too far.1
The label describes a Phase 3, multicenter, randomized trial in 162 adults with Cushing’s disease, 83% of whom had persistent or recurrent disease after pituitary surgery, comparing two treatment arms of Signifor for six months.1
At six months, 15% and 26% of patients in the two groups had normal average urine cortisol without needing an increase, and 34% and 41% met a less strict measure of response, according to the label.1
The trial had no placebo group, and about two-thirds of randomized patients completed six months, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Signifor, application NDA 200677, with an original approval date of December 14, 2012.2
The Signifor label cited here (DailyMed SPL version 20, published February 18, 2026) states that it is indicated for adults with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.1
The label has no boxed warning and lists no contraindications. Its warnings include low cortisol, high blood sugar and diabetes, slow heart rate and QT prolongation, and raised liver tests.1
How it compares with no treatment or other medicines: the trial described in the label compared two treatment arms of pasireotide without a placebo group.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Pasireotide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Pasireotide are a bounded selection, not every registration or paper about Pasireotide. For the years before Pasireotide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Pasireotide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Pasireotide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Signifor for Cushing’s disease. A randomized trial of 162 patients comparing two treatment arms, described in the label, found normal urine cortisol in 15% to 26% at six months. The label warns of high blood sugar and diabetes.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Signifor for Cushing’s disease. A randomized trial of 162 patients comparing two treatment arms, described in the label, found normal urine cortisol in 15% to 26% at six months. The label warns of high blood sugar and diabetes.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 31, 2026
Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.↗Source date October 31, 2026Literature metadata · added November 15, 2026
Pituitary acting drugs: cabergoline and pasireotide.↗Source date October 30, 2026Literature metadata · added November 15, 2026
Pasireotide: a review of its use in Cushing's disease.↗Source date October 11, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
29 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00171730 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-05, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00171951 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00434148 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-03-08, and PeptideScanner's reviewed identity mapping was pasireotide.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span October 17, 2012 to October 31, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 42778805 in Pituitary as Journal Article, with publication-date metadata of 2026-09-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35670988 in Pituitary as Journal Article, Review, with publication-date metadata of 2022-06-07 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23605695 in Drugs as Journal Article, Review, with publication-date metadata of 2013-05 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05928390 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was pasireotide.↗
Literature metadata
PubMed lists PMID 38713182 in Endocrine-related cancer as Journal Article, Multicenter Study, with publication-date metadata of 2024-05-27 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38577574 in Frontiers in endocrinology as Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-03-21 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06295952 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was pasireotide.↗
Literature metadata
PubMed lists PMID 23228667 in Diabetes & metabolism as Journal Article, Review, with publication-date metadata of 2012-12-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 27473537 in Drugs as Journal Article, Review, with publication-date metadata of 2016-09 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide.↗
Literature metadata
PubMed lists PMID 41323967 in Frontiers in endocrinology as Journal Article, with publication-date metadata of 2025-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40283624 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-04-18 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026